The Daily Inference
Science & Space · Analysis

Six of 15 Lung Cancer Samples Show No Living Cancer After Vaccine Combo

Early pancreatic and lung cancer trials show immune activity alongside melanoma's stronger clinical evidence. The next task is proving that adding a vaccine helps patients live longer or keeps their cancer from returning.

Follows About 12 More in 100 Melanoma Patients Stay Cancer-Free With a Custom Vaccine.

Experimental mRNA cancer vaccines have produced lasting immune responses in pancreatic cancer and encouraging pre-surgery results in lung cancer, extending the clinical promise of a platform already tested against melanoma. [1] [3]

In a pancreatic cancer study, vaccine-triggered immune cells remained detectable around three years after vaccination. In a preliminary lung cancer cohort, six of 15 patients whose surgical tissue was assessed had no viable cancer detected after a combination of vaccine, immunotherapy and chemotherapy. [1] [3]

These are treatments for people who already have cancer. The aim is to teach immune cells to recognize features of a tumor and attack cells carrying them. Some vaccines are made around an individual's tumor mutations, while others use targets shared across many tumors. [5]

The Daily Inference reported on October 23 that adding a vaccine tailored to each patient's tumor improved outcomes after surgery for high-risk melanoma. The pancreatic and lung findings widen the question: how far can this strategy travel across cancers with different biology and different treatment needs? [1] [3] [5]

Our reading is that therapeutic mRNA vaccines have earned serious clinical testing. The case now rests on measurable immune activity and, in melanoma, a randomized comparison with an existing treatment. The strongest reason for optimism is the combination of those two kinds of evidence: an immune system learning a target, and a clinical result suggesting that the lesson can matter. [1] [6]

Giving immune cells a target

The mRNA platform gained manufacturing experience and public visibility through COVID-19 vaccines. Treating an established tumor poses a different problem from preventing an infection. Tumors vary, can suppress immune responses and may lose the features a treatment targets. [5]

A personalized cancer vaccine starts with tumor tissue. Researchers analyze its mutations and select features that could distinguish cancer cells from other cells. These targets are called neoantigens, meaning newly arising features that the immune system can recognize. [1] [5]

The vaccine carries mRNA instructions for making proteins containing those selected targets. Cells use the instructions, make the proteins and present them to the immune system. The intended result is to activate T cells, immune cells capable of recognizing and attacking cancer cells carrying the same features. [1] [5]

That is why a cancer vaccine need not act directly on the tumor to be useful. Its immediate job is to change what the immune system recognizes. Researchers can then look for evidence of that change in blood and tissue, as well as measuring what happens to the cancer. [1] [5]

Personalization is one route. BioNTech's experimental lung cancer vaccine, BNT116, instead encodes tumor-associated antigens shared across tumors. It is designed around common targets rather than the unique mutation pattern of each participant. Both approaches try to supply the immune system with a usable description of its target. [3] [4] [5]

Choosing that description is a central research problem. A 2026 review in Frontiers in Oncology identifies target selection, immune-response monitoring and tests that predict benefit as unresolved challenges. It describes a broad research landscape across melanoma, pancreatic cancer, lung cancer and other solid tumors. [5]

The practical question is whether the selected targets provoke an attack that remains useful as the cancer changes. A vaccine that generates an impressive blood-test result still has to improve an outcome patients can feel.

Melanoma supplies the stronger test

The strongest clinical evidence among these examples comes from a randomized phase 2b melanoma trial involving 157 people whose high-risk cancers had been surgically removed. It compared the individualized vaccine mRNA-4157, also called V940, plus pembrolizumab with pembrolizumab alone. Pembrolizumab is an immune checkpoint inhibitor, a treatment intended to strengthen the immune response against cancer. [6] [5]

At 18 months, recurrence-free survival was 79% in the combination group and 62% in the group receiving pembrolizumab alone. That endpoint counts time without either a cancer recurrence or death. The difference was 17 percentage points, equivalent to 17 more people per 100 being recurrence-free at that point. [6]

Random allocation gives this comparison more weight than a study in which everyone receives the experimental treatment. It tests the addition of the vaccine against the same underlying therapy, reducing the scope for differences between patients to explain the result.

There is a statistical wrinkle worth keeping in proportion. The reported P value was 0.053, close to but above the conventional 0.05 threshold. That threshold is a rule used to judge evidence against a no-difference assumption. Missing it narrowly does not erase the observed gap, but the result calls for confirmation rather than a declaration of victory. [6]

The clinical question is substantial. After surgery has removed the visible cancer, can a vaccine help the immune system deal with cancer cells that might remain? The melanoma comparison offers a reason to pursue that possibility in larger and longer studies. [6]

Across these trials, longer overall survival, benefit for most patients and a cure have not been established. The studies involve different cancers, vaccines and treatment combinations, so their percentages cannot be ranked as though they came from one contest. The pancreatic responder comparison is observational, while the lung cohort has no comparison group that separates the vaccine's contribution from the other treatments. [1] [3] [6]

Pancreatic cancer's long-lived response

The pancreatic study offers a different kind of evidence: a detailed view of an immune response that lasted.

A peer-reviewed Nature paper followed 16 vaccinated participants with pancreatic ductal adenocarcinoma. They received treatment after surgery, alongside the checkpoint inhibitor atezolizumab and modified FOLFIRINOX chemotherapy. Eight developed high-magnitude vaccine-induced T-cell responses. [1] [2]

At a median follow-up of 3.2 years, median recurrence-free survival had not been reached in those eight responders. Among the eight non-responders, it was 13.4 months. "Not reached" means that the observed recurrence-or-death events had not yet brought the estimated recurrence-free proportion down to half. It does not mean every responder was free of cancer. [1]

The comparison is striking, but the groups were defined by whether their immune systems responded, rather than assigned randomly. A person's ability to mount that response could itself be related to their outcome. The association therefore supports a hypothesis about benefit without establishing that the vaccine caused the difference. [1]

The researchers also tracked vaccine-triggered T-cell clones, groups of cells descended from the same responding cell, in blood and tissue. Many remained detectable around three years after vaccination and retained cancer-targeting function. [1]

This is the finding that gives the pancreatic work particular force. The immune response was durable and functional. That supplies a biological reason to test whether it can translate into reliable protection against recurrence. [1]

It also sharpens the next research question. Only half of the 16 vaccinated participants developed the high-magnitude response. Finding out who is likely to respond, and whether that can be predicted before treatment, could be as important as refining the vaccine itself. The broader research review identifies predictive biomarkers, measurable signs in a tumor or blood sample, as an unresolved need. [1] [5]

Lung cancer brings the test before surgery

The lung cancer findings come from 20 people with resectable stage II or III non-small-cell lung cancer in a phase 1 cohort of LuCa-MERIT-1. Participants received BNT116 with the checkpoint inhibitor cemiplimab and carboplatin-paclitaxel chemotherapy before surgery. Preliminary results were presented at the 2026 World Conference on Lung Cancer, according to the patient advocacy organization Happy Lungs Project. [3]

Before surgery, scans showed a partial response in 13 participants and stable disease in seven. Surgical tissue was available for 15. Eight had a major pathological response, meaning a substantial treatment response found by examining the tissue, including six with no viable cancer detected. [3]

Those denominators matter. Six of 15 assessed tissue samples showed no viable cancer. That is not a result for all 20 participants, and an examination at surgery is a different measurement from following patients for recurrence or survival.

Immune-response data were available for 12 participants. Eight showed a response against at least one antigen targeted by the vaccine, according to Happy Lungs Project's account. The median follow-up was 14.5 months. [3]

The treatment also imposed a burden. Common treatment-emergent side effects included fever, chills, neutropenia, a low level of certain white blood cells, and fatigue. No treatment-related delay to surgery occurred in this cohort, according to the same account. Keeping surgery on track matters when an experimental treatment is added before an operation. [3]

The lung work is the earliest clinical signal of the three examples. It offers tumor measurements, tissue findings and immune-response data that justify further testing, rather than a settled estimate of how much BNT116 helps.

BioNTech lists the wider first-in-human BNT116 study as recruiting, with estimated enrollment of 320 across several lung cancer settings and treatment combinations. Its estimated study dates run from June 2022 to February 2030. That planned scale is much larger than this 20-person cohort, though the trial page itself is evidence of research activity, not effectiveness. [4]

The next decisive step is to establish the added value of vaccination: fewer recurrences, longer survival, an acceptable treatment burden and a clearer way to identify likely responders. Larger comparisons and longer follow-up must now turn these early signals into a treatment decision. [1] [3] [5] [6]

The story so far 2 pieces since October 23, 2026, in order

Topics: Medical research · Cancer vaccines · Melanoma

Every edition in brief, three times a day, on our Telegram channel, on Bluesky and on Threads.

Sources
  1. RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer | Nature nature.com
  2. Investigational Pancreatic Cancer Vaccine Shows Lasting Results in Early Trial, Supporting Continued Testing | Memorial Sloan Kettering Cancer Center mskcc.org
  3. BioNTech Cancer Vaccine - Promising Activity in Resectable NSCLC happylungsproject.org
  4. BioNTech | Trial ID BNT116-01 clinicaltrials.biontech.com
  5. Frontiers | Progress on therapeutic mRNA vaccines for cancer frontiersin.org
  6. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. bjsacademy.com